FAQ: APO-go® (apomorphine hydrochloride) therapies during the COVID-19 pandemic
FAQ for healthcare professionals: APO-go® (apomorphine hydrochloride) therapies during the COVID-19 pandemic.
Last reviewed
Topic
- Treatments and medication
Resource type
- Publications
Profession
- All professions
Stage
- Complex
This frequently asked questions document covers queries that healthcare professionals may receive from patients regarding APO-go® (apomorphine hydrochloride) products during the COVID-19 pandemic.
This document has been made available by Britannia Pharmaceuticals for use by healthcare professionals.
By clicking to to download the below document you are confirming that you are a healthcare professional.
Please note the FAQ is currently being revised and the updated version will be available soon.
More conferences for professionals
Explore a range of conferences and events for professionals